Graves' orbitopathy: a multidisciplinary approach
Q J Nucl Med Mol Imaging. 2021 Feb 26. doi: 10.23736/S1824-4785.21.03350-1. Online ahead of print.ABSTRACTOrbitopathy is the main extra thyroidal manifestation of Graves' disease. It is a very challenging condition, which requires a cooperation between many specialists (endocrinologists, ophthalmologists, radiologists, radiotherapeutic, orbital surgeons) for its adequate clinical management. An accurate diagnostic assessment is required, in order to plan an adequate treatment of Graves' orbitopathy. Medical therapy, radiotherapy or surgery may be necessary to control the disease. In this review, the authors analyze the var...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - February 26, 2021 Category: Nuclear Medicine Authors: Paolo P Limone Marco Mellano Maria G Ruo Redda Annalisa Macera Vittorio Ferrero Stefano Sellari Franceschini Maurilio Deandrea Source Type: research

Update on diagnosis and treatment of hyperthyroidism
Q J Nucl Med Mol Imaging. 2021 Feb 26. doi: 10.23736/S1824-4785.21.03351-3. Online ahead of print.NO ABSTRACTPMID:33634674 | DOI:10.23736/S1824-4785.21.03351-3 (Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging)
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - February 26, 2021 Category: Nuclear Medicine Authors: Luca Giovanella Source Type: research

Graves' orbitopathy: a multidisciplinary approach
Q J Nucl Med Mol Imaging. 2021 Feb 26. doi: 10.23736/S1824-4785.21.03350-1. Online ahead of print.ABSTRACTOrbitopathy is the main extra thyroidal manifestation of Graves' disease. It is a very challenging condition, which requires a cooperation between many specialists (endocrinologists, ophthalmologists, radiologists, radiotherapeutic, orbital surgeons) for its adequate clinical management. An accurate diagnostic assessment is required, in order to plan an adequate treatment of Graves' orbitopathy. Medical therapy, radiotherapy or surgery may be necessary to control the disease. In this review, the authors analyze the var...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - February 26, 2021 Category: Nuclear Medicine Authors: Paolo P Limone Marco Mellano Maria G Ruo Redda Annalisa Macera Vittorio Ferrero Stefano Sellari Franceschini Maurilio Deandrea Source Type: research

Update on diagnosis and treatment of hyperthyroidism
Q J Nucl Med Mol Imaging. 2021 Feb 26. doi: 10.23736/S1824-4785.21.03351-3. Online ahead of print.NO ABSTRACTPMID:33634674 | DOI:10.23736/S1824-4785.21.03351-3 (Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging)
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - February 26, 2021 Category: Nuclear Medicine Authors: Luca Giovanella Source Type: research

Graves' orbitopathy: a multidisciplinary approach
Q J Nucl Med Mol Imaging. 2021 Feb 26. doi: 10.23736/S1824-4785.21.03350-1. Online ahead of print.ABSTRACTOrbitopathy is the main extra thyroidal manifestation of Graves' disease. It is a very challenging condition, which requires a cooperation between many specialists (endocrinologists, ophthalmologists, radiologists, radiotherapeutic, orbital surgeons) for its adequate clinical management. An accurate diagnostic assessment is required, in order to plan an adequate treatment of Graves' orbitopathy. Medical therapy, radiotherapy or surgery may be necessary to control the disease. In this review, the authors analyze the var...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - February 26, 2021 Category: Nuclear Medicine Authors: Paolo P Limone Marco Mellano Maria G Ruo Redda Annalisa Macera Vittorio Ferrero Stefano Sellari Franceschini Maurilio Deandrea Source Type: research

Update on diagnosis and treatment of hyperthyroidism
Q J Nucl Med Mol Imaging. 2021 Feb 26. doi: 10.23736/S1824-4785.21.03351-3. Online ahead of print.NO ABSTRACTPMID:33634674 | DOI:10.23736/S1824-4785.21.03351-3 (Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging)
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - February 26, 2021 Category: Nuclear Medicine Authors: Luca Giovanella Source Type: research

Graves' orbitopathy: a multidisciplinary approach
Q J Nucl Med Mol Imaging. 2021 Feb 26. doi: 10.23736/S1824-4785.21.03350-1. Online ahead of print.ABSTRACTOrbitopathy is the main extra thyroidal manifestation of Graves' disease. It is a very challenging condition, which requires a cooperation between many specialists (endocrinologists, ophthalmologists, radiologists, radiotherapeutic, orbital surgeons) for its adequate clinical management. An accurate diagnostic assessment is required, in order to plan an adequate treatment of Graves' orbitopathy. Medical therapy, radiotherapy or surgery may be necessary to control the disease. In this review, the authors analyze the var...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - February 26, 2021 Category: Nuclear Medicine Authors: Paolo P Limone Marco Mellano Maria G Ruo Redda Annalisa Macera Vittorio Ferrero Stefano Sellari Franceschini Maurilio Deandrea Source Type: research

Update on diagnosis and treatment of hyperthyroidism
Q J Nucl Med Mol Imaging. 2021 Feb 26. doi: 10.23736/S1824-4785.21.03351-3. Online ahead of print.NO ABSTRACTPMID:33634674 | DOI:10.23736/S1824-4785.21.03351-3 (Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging)
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - February 26, 2021 Category: Nuclear Medicine Authors: Luca Giovanella Source Type: research

Graves' orbitopathy: a multidisciplinary approach
Q J Nucl Med Mol Imaging. 2021 Feb 26. doi: 10.23736/S1824-4785.21.03350-1. Online ahead of print.ABSTRACTOrbitopathy is the main extra thyroidal manifestation of Graves' disease. It is a very challenging condition, which requires a cooperation between many specialists (endocrinologists, ophthalmologists, radiologists, radiotherapeutic, orbital surgeons) for its adequate clinical management. An accurate diagnostic assessment is required, in order to plan an adequate treatment of Graves' orbitopathy. Medical therapy, radiotherapy or surgery may be necessary to control the disease. In this review, the authors analyze the var...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - February 26, 2021 Category: Nuclear Medicine Authors: Paolo P Limone Marco Mellano Maria G Ruo Redda Annalisa Macera Vittorio Ferrero Stefano Sellari Franceschini Maurilio Deandrea Source Type: research

Update on diagnosis and treatment of hyperthyroidism
Q J Nucl Med Mol Imaging. 2021 Feb 26. doi: 10.23736/S1824-4785.21.03351-3. Online ahead of print.NO ABSTRACTPMID:33634674 | DOI:10.23736/S1824-4785.21.03351-3 (Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging)
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - February 26, 2021 Category: Nuclear Medicine Authors: Luca Giovanella Source Type: research

Graves' orbitopathy: a multidisciplinary approach
Q J Nucl Med Mol Imaging. 2021 Feb 26. doi: 10.23736/S1824-4785.21.03350-1. Online ahead of print.ABSTRACTOrbitopathy is the main extra thyroidal manifestation of Graves' disease. It is a very challenging condition, which requires a cooperation between many specialists (endocrinologists, ophthalmologists, radiologists, radiotherapeutic, orbital surgeons) for its adequate clinical management. An accurate diagnostic assessment is required, in order to plan an adequate treatment of Graves' orbitopathy. Medical therapy, radiotherapy or surgery may be necessary to control the disease. In this review, the authors analyze the var...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - February 26, 2021 Category: Nuclear Medicine Authors: Paolo P Limone Marco Mellano Maria G Ruo Redda Annalisa Macera Vittorio Ferrero Stefano Sellari Franceschini Maurilio Deandrea Source Type: research

Update on diagnosis and treatment of hyperthyroidism
Q J Nucl Med Mol Imaging. 2021 Feb 26. doi: 10.23736/S1824-4785.21.03351-3. Online ahead of print.NO ABSTRACTPMID:33634674 | DOI:10.23736/S1824-4785.21.03351-3 (Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging)
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - February 26, 2021 Category: Nuclear Medicine Authors: Luca Giovanella Source Type: research

Radioiodine therapy of Graves' disease.
Authors: Piccardo A, Ugolini M, Altrinetti V, Righi S, Fiz F, Foppiani L, Giovanella L Abstract Graves' disease (GD), the most common cause of hyperthyroidism, is an autoimmune disease directly caused by circulating autoantibodies that bind and activate the TSH receptor, inducing metabolic activation of the thyroid gland; this may be associated with important cardiac (atrial fibrillation) and ocular (ophthalmopathy) complications. Treating GD with real curative intent implies the full elimination of the functioning thyroid parenchyma using surgery or radioactive iodine therapy (RAI). RAI has been used in humans wit...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - February 12, 2021 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Radioiodine Therapy (RIT) of thyroid autonomy.
Authors: Clerc J Abstract Radioiodine Therapy (RIT) of Thyroid Functional Autonomy (TFA) is rapidly evolving, though it has been recognized for decades as a very effective treatment of toxic nodular varieties. Indeed, TFA is a frequent cause of persistent subclinical hyperthyroidism, which should be regarded as a new metabolic syndrome, with well-established adverse cardio-vascular consequences. Sensitive TSH assays and MultiParametric Ultra-Sounds are not accurate enough to reliably diagnose TFA and identify its main variants, unifocal, multifocal (UFA/MFA) and disseminated autonomy (DISA). Modern diagnostic tools...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - February 12, 2021 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

The role of the laboratory medicine in the diagnosis of the hyperthyroidism.
Authors: D'Aurizio F Abstract Hyperthyroidism is a clinical condition characterized by inappropriately high synthesis and secretion of thyroid hormones by the thyroid gland. It has multiple aetiologies, manifestations and potential therapies. Graves' disease is the most common form of hyperthyroidism, due to the production of autoantibodies against thyrotropin receptor, capable of over-stimulating thyroid function. A reliable diagnosis of hyperthyroidism can be established on clinical grounds, followed by the evaluation of serum thyroid functional tests (thyrotropin first and then free thyroxine, adding the measure...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - February 12, 2021 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Interventional nuclear medicine: a focus on radioguided intervention and surgery.
Authors: Rietbergen DD, van Oosterom MN, Kleinjan GH, Brouwer OR, Valdes-Olmos RA, van Leeuwen FW, Buckle T Abstract Within Interventional Nuclear Medicine (iNM) a prominent role is allocated for the subdiscipline of radioguided surgery. Unique for this discipline is the fact that an increasing number of clinical indications (e.g. lymphatic mapping, local tumor demarcation and/or tumor receptor targeted applications) have been adopted into routine care. The clinical integration is further strengthened by technical innovations in chemistry and engineering that enhance the translational potential of radioguided proce...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - January 27, 2021 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Practice and prospects for PET/CT guided interventions.
Authors: Bogoni M, Cerci JJ, Cornelis FH, Nanni C, Tabacchi E, SchȌder H, Shyn PB, Sofocleous CT, Solomon SB, Kirov AS Abstract During the past 10 years, performing real-time molecular imaging with positron emission tomography (PET) in combination with computed tomography (CT) during interventional procedures has undergone rapid development. Keeping in mind the interest of the nuclear medicine readers, an update is provided of the current workflows using real-time PET/CT in percutaneous biopsies and tumor ablations. The clinical utility of PET/CT guided biopsies in cancer patients with lung, liver, lymphoma, and b...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - January 27, 2021 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Interventional nuclear medicine.
Authors: Kirov AS, SchÖder H, Solomon SB, Sattler B PMID: 33494586 [PubMed - as supplied by publisher] (Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging)
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - January 27, 2021 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Current approach to surgical management of hyperthyroidism.
Authors: BarczyŃski M Abstract Hyperthyroidism is a set of disorders that involve excess synthesis and secretion of thyroid hormones by the thyroid gland, which leads to thyrotoxicosis. The most common forms of hyperthyroidism include diffuse toxic goiter (Graves' disease), toxic multinodular goiter (Plummer disease), and a solitary toxic adenoma. The most reliable screening measure of thyroid function is the thyroid-stimulating hormone (TSH) level. Options for treatment of hyperthyroidism include: antithyroid drugs, radioactive iodine therapy (the preferred treatment of hyperthyroidism among US thyroid specialist...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - January 27, 2021 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Update on diagnosis and treatment of hyperthyroidism. Ultrasonography and functional imaging.
Authors: Schenke SA, GÖrges R, Seifert P, Zimny M, Kreissl MC Abstract Both, ultrasonography but also radionuclide imaging using [99mTc]Pertechnetate or radioactive iodine isotopes are essential tools used during the diagnostic workup of hyperthyroidism with or without structural alterations of the thyroid. Colour duplex sonography and ultrasound elastography may add important information in order to find the cause of the hormone excess. During the last years, also hybrid imaging using SPECT/-(CT) or PET-based methods, such as [124]Iodine-PET/CT or [124]Iodine-PET/ultrasound also have nodularbeen increasingly ...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - January 27, 2021 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Medical treatment of thyrotoxicosis.
Authors: Scappaticcio L, Bellastella G, Maiorino MI, Giovanella L, Esposito K Abstract Medical treatment is the primary therapeutic option for thyrotoxicosis/hyperthyroidism. Two groups of causes of thyrotoxicosis (i.e. thyrotoxicosis with hyperthyroidism and thyrotoxicosis without hyperthyroidism) need to be considered for therapeutic reasons. Herein we provide an updated review on the role of conventional medical therapies [i.e. β-blockers, anti-thyroid drugs (ATDs), corticosteroids, inorganic iodide, perchlorate, cholecystographic agents, lithium, cholestyramine] in the main causes of thyrotoxicosis, starti...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - January 27, 2021 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Review of lung shunt and lung dose calculation methods for radioembolization treatment planning.
We present a systematic review of the various methods of determining the lung shunt fraction (LSF) and lung mean dose (LD). This review encompasses pre-therapy estimations and post-therapy assessments of the LSF and LD using both 2D planar and 3D SPECT/CT based calculations. The advantages and limitations of each of these methods are deliberated with a focus on accuracy and practical considerations. We conclude the review with the presentation of a lexicon to precisely describe the methodology used for the estimation of LSF and LD; specifically, category, agent, modality, contour, and algorithm, to aid in their interpretat...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - January 6, 2021 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

F18-FET PET in pediatric brain tumors: integrative analysis of image derived parameters and clinico-pathological data.
CONCLUSIONS: F18-FET PET seems to be an evolving pediatric neuroimaging technique with valuable diagnostic & prognostic information at initial and post-therapy evaluation. PMID: 33300749 [PubMed - as supplied by publisher] (Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging)
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - December 12, 2020 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Practical setting and potential applications of interventions guided by PET/MRI.
CONCLUSIONS: Most PET/MRI sites could allow for interventions with just a few addons and modifications, such as comunication, in room image display and sytems control. By unlocking this feature, and driving preclinical research in interventional PET/MRI, translation of the protocol and methodology into clinical settings seems feasible. PMID: 33300750 [PubMed - as supplied by publisher] (Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging)
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - December 12, 2020 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

64Copper labelled nanoparticles for PET Imaging: a review of the recent literature.
CONCLUSIONS: The results showed that nanoparticles can be considered a promising radiopharmaceutical for PET imaging of different type of cancer. PMID: 33073558 [PubMed - as supplied by publisher] (Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging)
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - October 21, 2020 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Adding copper-64 radiopharmaceuticals to the toolkit of molecular imaging.
Authors: Capriotti G, Duatti A PMID: 33073559 [PubMed - as supplied by publisher] (Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging)
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - October 21, 2020 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

64Cu-immunoPET imaging: bench to bedside.
Authors: Natarajan A Abstract Positron emission tomography (PET) is a growing non-invasive diagnostic and molecular imaging tool in nuclear medicine, that is used to identify several diseases including cancer. The immunoPET probe is made up of monoclonal antibodies (mAbs) or its fragments or similar molecules that tagged with positron radioisotopes (68Ga, 64Cu, 89Zr) bound together by a bifunctional chelator (BFC). This probe is designed to identify a specific disease. Currently, several immunoPET probes are being developed for pre-clinical as well as for clinical applications. These studies are showing promising r...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - October 15, 2020 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Peptide and pseudo-peptide (PSMA) Cu-64 radiopharmaceuticals.
Authors: Mirzaei S, Lipp RW Abstract In recent years, the introduction of theranostic twins for specific diagnosis and treatment in patients with neuroendocrine tumors became a nuclear medicine success story. 64Cu/18F labeled prostate specific membrane antigen (PSMA) for molecular imaging with PET-CT and peptide radioligand therapy with 177Lu labeled PSMA inhibitors will favorably become the next theranostic twins in nuclear medicine history. 68Ga/ 64Cu/18F PSMA PET/CT detects metastatic prostate cancer with high diagnostic sensitivity and specificity. In addition, it can be used to select patients for radioligand ...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - October 15, 2020 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Copper-64 based radiopharmaceuticals for brain tumors and hypoxia imaging.
CONCLUSIONS: Among radio copper compounds [64Cu][Cu(ATSM)] is the most studied radiopharmaceutical for imaging and treatment of brain tumors. Experimental evidence suggested that [64Cu][Cu(ATSM)] could be more appropriately considered as a marker of over-reduced intracellular state rather than a pure hypoxia agent. Moreover, preliminary clinical data suggested that [64Cu]CuCl2 can be a potentially useful diagnostic agent for malignancies of the central nervous system (CNS). PMID: 33026209 [PubMed - as supplied by publisher] (Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging)
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - October 9, 2020 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

The emerging value of copper-64 for molecular imaging and therapy.
Authors: Bolzati C, Duatti A Abstract Along with other novel metallic radionuclides, copper-64 (64Cu) is currently being investigated as an alternative option to the gallium-68 (68Ga) and lutetium-177 (177Lu) radiopharmaceuticals widely used for targeting somatostatin receptors, expressed by neuroendocrine tumors (NETs), and recently prostate specific membrane antigen (PSMA), expressed by prostate cancer cells. This interest is mostly driven by the peculiar nuclear properties of 64Cu that make it an almost ideal example of theranostic radionuclide. In fact, 64Cu emits both low-energy positrons, β- particles an...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - October 9, 2020 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

IAEA contribution to the development of copper-64 radiopharmaceuticals for theranostic applications.
Authors: Jalilian AR, Osso JA, Vera-Araujo J, Kumar V, Harris MJ, Gutfilen B, Guérin B, Li H, Zhuravlev F, Chakravarty R, Alirezapour B, Ávila-Rodríguez MA, Khan IU, Aljammaz I, Assaad T, Luurtsema G, Smith J, Duatti A Abstract Copper-64 is a very attractive radioisotope with unique nuclear properties that allow using it as both a diagnostic and therapeutic agent, thus providing an almost ideal example of a theranostic radionuclide. A characteristic of Cu-64 stems from the intrinsic biological nature of copper ions that play a fundamental role in a large number of cellular processes. Cu-64 is a...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - October 9, 2020 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Copper, PET/CT and prostate cancer. A systematic review of the literature.
Authors: Piccardo A, Ugolini M, Righi S, Bottoni G, Cistaro A, Paparo F, Giovanella L, Evangelista L Abstract Copper is an essential element that plays an important role in both cancer development and growth. Indeed, high levels of copper have been found in prostate cancer (PCa), and this finding have paved the way for the use of this element as a target for positron emission tomography (PET) imaging. Copper64 (64Cu) can be used alone, as 64CuCl2, and also as a precursor for the in vitro radio-labelling of specific carriers for PET imaging in PCa, (e.g. associated to prostate-specific membrane antigen: PSMA). The u...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - September 12, 2020 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Managing radioiodine refractory thyroid cancer: the role of dosimetry and redifferentiation on subsequent I-131 therapy.
We describe the role of dosimetry in redifferentiation and subsequent I-131 therapy in RAI-R thyroid cancer, explain different dosimetry approaches and discuss limitations and considerations in the field. PMID: 32744039 [PubMed - in process] (Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging)
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - August 4, 2020 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Using 99mTc-(V)-DMSA to follow the vascular calcification process in vascular smooth muscle cells based on pit-1 expression.
Authors: Bonnefoy PB, Jacqueroux E, Delavenne X, Roche F, Clotagatide A, Mismetti P, Prevot N, Perek N Abstract BACKGROUND: Vascular calcification is an established feature of atherosclerosis process. The sodium/phosphate transporter PiT-1 acts as a biosensor in vascular calcification of VSMCs. [99mTc]-Pentavalent dimercaptosuccinic acid (99mTc-(V)-DMSA) was mediated by PiT-1 transporter in tumoral cells and we propose its evaluation in a vascular calcification in vitro model. The aim of this study was to determine if 99mTc-(V)-DMSA can follow the vascular calcification process in vascular smooth muscle cells (VSMC...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - June 18, 2020 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Choline PET/CT features to predict survival outcome in high risk prostate cancer restaging: a preliminary machine-learning radiomics study.
CONCLUSIONS: An artificial intelligence model demonstrated to be feasible and able to select a panel of 18F-Cho PET/CT features with valuable association with PCa patients' outcome. PMID: 32543166 [PubMed - as supplied by publisher] (Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging)
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - June 18, 2020 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Targeted Alpha Therapy: a critical review of translational dosimetry research with emphasis on Actinium-225.
Authors: Seoane DC, De Saint-Hubert M, Crabbe M, Struelens L, Koole M Abstract This review provides a general overview of the current achievements and challenges in translational dosimetry for Targeted Alpha therapy (TAT). The concept of Targeted Radionuclide Therapy (TRNT) is described with an overview of its clinical applicability and the added value of TAT is discussed. For TAT, we focused on 225Ac (actinium-225) as an example for alpha particle emitting radionuclides and their features, such as limited range within tissue and high linear energy transfer, which make alpha particle emissions more effective in tar...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - May 23, 2020 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Prognostic and predictive role of the tumor immune landscape.
Authors: Haanen JB, Blank CU Abstract Cancer immunotherapy utilizing immune checkpoint inhibitors, has become mainstay for a growing number of cancer types. However, in general, the objective response rate and survival is only improved in a minority of cancer patients. Many of the biomarkers to select patients that either benefit or do not, have next to being predictive also prognostic value, are continuous instead of categorical, and are therefore difficult to use in daily practice. Currently, PD-L1 by immunohistochemical staining is the only approved biomarker to select metastatic non-small cell lung cancer patie...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - May 19, 2020 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Molecular imaging of norepinephrine transporter-expressing tumors: current status and future prospects.
Authors: Pauwels E, van Aerde M, Bormans G, Deroose CM Abstract The human norepinephrine transporter (hNET) is a transmembrane protein responsible for reuptake of norepinephrine in presynaptic sympathetic nerve terminals and adrenal chromaffin cells. Neural crest tumors, such as neuroblastoma, paraganglioma and pheochromocytoma often show high hNET expression. Molecular imaging of these tumors can be done using radiolabeled norepinephrine analogs that target hNET. Currently, the most commonly used radiopharmaceutical for hNET imaging is meta-[123I]iodobenzylguanidine ([123I]MIBG) and this has been the case since it...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - May 15, 2020 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Nuclear medicine radiomics in precision medicine: why we can't do without artificial intelligence.
Authors: Noortman WA, Vriens D, Grootjans W, Tao Q, De Geus-Oei LF, van Velden FH Abstract In recent years, radiomics, defined as the extraction of large amounts of quantitative features from medical images, has gained emerging interest. Radiomics consists of the extraction of handcrafted features combined with sophisticated statistical methods or machine learning algorithms for modelling, or deep learning algorithms that both learn features from raw data and perform modelling. These features have the potential to serve as non-invasive biomarkers for tumour characterisation, prognostic stratification and response p...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - May 15, 2020 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Nuclear medicine in precision oncology.
Authors: de Geus-Oei LF, Deroose CM PMID: 32343513 [PubMed - as supplied by publisher] (Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging)
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - April 29, 2020 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Characterization of heterogeneity of hypoxia with 18FMISO PET/CT, BOLD fMRI and immunohistochemistry in human breast tumor xenograft: initial study.
Authors: Cheng J, Zhang J, He S, Qi M, Zhang Y, Zhu X, Zhang Y, Zhang J, Geng D Abstract BACKGROUND: To demonstrate that both 18F-fluoromisonidazole positron emission tomography computed tomography (18F-MISO PET/CT) and function magnetic resonance imaging blood oxygenation level dependent (fMRI BOLD) can map intratumoral sub-region of hypoxia consistently. METHODS: The MCF-7 xenograft was established and hypoxia were divided into three subtypes by animal 18F-MISO PET/CT scan. Using tumor to background ratio (TBR)>1.40 and hypoxia sub-volume (HSV) / tumor volume (TV) ≧ 50% as threshold, hypoxia was divided ...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - April 15, 2020 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Volumetric 68Ga-DOTA-TATE PET/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with metastatic gastroenteropancreatic neuroendocrine tumors.
CONCLUSIONS: SSR-derived volumetric parameters provide a quantitative imaging biomarker for whole-body tumor burden, and may hold potential as a clear-cut measure for assessment of treatment response. PMID: 32286768 [PubMed - as supplied by publisher] (Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging)
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - April 15, 2020 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Preclinical imaging for targeting cancer immune evasion.
Authors: Terlizzi C, De Rosa V, Iommelli F, Altobelli GG, Fonti R, Del Vecchio S Abstract Novel anticancer immunotherapy strategies such as immune checkpoint blockade have been successfully employed in patients with a variety of cancers and became a therapeutic option in the treatment of several malignancies. However, long-term durable responses to immune checkpoint inhibitors are currently limited to a fraction of patients raising the need of an accurate selection of potentially responding patients. Although several biomarkers have been proposed for patient selection and prediction of response to immune checkpoint...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - April 15, 2020 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Immunoscore and its introduction in clinical practice.
Authors: Galon J, Lanzi A Abstract Current cancer classification is based on intrinsic tumor parameters such as characteristic of tumor cells, tumor progression, tumor invasion and the presence of distant metastases, as summarized by the AJCC/UICC-TNM stratification system. There is currently no immune- based classification of cancer. We provided evidence that the immune contexture, as defined by the type, density, functional immune orientation and the location of immune cells within tumor, strongly influences the outcome of colorectal cancer (CRC) patients. To translate this information to the clinic, we developed...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - February 29, 2020 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors.
Authors: Benitez JC, Recondo G, Rassy E, Mezquita L Abstract In the last decade, immune checkpoint inhibitors (ICI) have completely changed the treatment strategy and the prognosis of several solid cancer types. There is a lack of biomarkers to differ between responders and non-responders to these therapies. The development of biomarkers for immunotherapy has been mainly focused on tumor-related factors. The role of PD-L1 expression or tumor mutational burden (TMB) as potential predictive biomarkers for ICI efficacy is not universal and remains controversial. Moreover, leukocyte and neutrophil counts in blood sampl...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - February 29, 2020 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Update on tumor metabolism and patterns of response to immunotherapy.
Authors: Castello A, Lopci E Abstract Immune checkpoint inhibitors (ICI) represent a cornerstone in cancer treatment. However, the peculiarity of immune response, determining distinctive response patterns and toxicity events, challenges the conventional response criteria. Therefore, the effective tumor response and the real clinical benefit cannot be demonstrated adequately. In this context, recent studies using 2-deoxy-2-[18F]fluoro-D-glucose ([18F]) positron emission tomography/computed tomography (PET/CT) have shown promising results for therapeutic monitoring during ICI, although further research is needed to c...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - February 29, 2020 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Cancer management in the era of immunotherapy: "much more than what strikes the eyes".
Cancer management in the era of immunotherapy: "much more than what strikes the eyes". Q J Nucl Med Mol Imaging. 2020 Feb 27;: Authors: Lopci E, Haanen J PMID: 32107905 [PubMed - as supplied by publisher] (Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging)
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - February 29, 2020 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Clinical imaging of cardiovascular inflammation.
Authors: Calcagno C, Fayad ZA Abstract Cardiovascular disease due to atherosclerosis is the number one cause of morbidity and mortality worldwide. In the past twenty years, compelling preclinical and clinical data have indicated that a maladaptive inflammatory response plays a crucial role in the development of atherosclerosis initiation and progression in the vasculature, all the way to the onset of life-threatening cardiovascular events. Furthermore, inflammation is key to heart and brain damage and healing after myocardial infarction or stroke. Recent evidence indicates that this interplay between the vasculatur...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - February 22, 2020 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Current and novel radiopharmaceuticals for imaging cardiovascular inflammation.
Authors: Heo GS, Sultan D, Liu Y Abstract Cardiovascular disease (CVD) remains the leading cause of death worldwide despite advances in diagnostic technologies and treatment strategies. The underlying cause of most CVD is atherosclerosis, a chronic disease driven by inflammatory reactions. Atherosclerotic plaque rupture could cause arterial occlusion leading to ischemic tissue injuries such as myocardial infarction (MI) and stroke. Clinically, most imaging modalities are based on anatomy and provide limited information about the on-going molecular activities affecting the vulnerability of atherosclerotic lesion for...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - February 22, 2020 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research

Inflammation imaging to define vulnerable plaque or vulnerable patient.
Authors: Vigne J, Hyafil F Abstract The role of nuclear imaging in the characterization of high risk atherosclerotic plaque is increasing thanks to its high sensitivity to detect radiopharmaceuticals signal in tissues. Currently, 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) is the most studied and widely used radiopharmaceutical for the molecular imaging of atherosclerotic plaques with positron emission tomography (PET). [18F]FDG PET is a valuable tool to non-invasively detect, monitor and quantify inflammatory processes occurring in atherosclerotic plaques. The aim of this review is to gather insights provided by [1...
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - February 22, 2020 Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research